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 Abstract 
The endothelium is a cellular monolayer that lines the inner surface of blood vessels and 
plays a central role in the maintenance of cardiovascular homeostasis by controlling platelet 
aggregation, vascular tone, blood fluidity and fibrinolysis, adhesion and transmigration of 
inflammatory cells, and angiogenesis. Endothelial dysfunctions are associated with various 
cardiovascular diseases, including atherosclerosis, hypertension, myocardial infarction, and 
cardiovascular complications of diabetes. Numerous studies have established the anti-
inflammatory, anti-apoptotic, and anti-oxidant effects of hydrogen sulfide (H2S), the latest 
member to join the gasotransmitter family along with nitric oxide and carbon monoxide, on 
vascular endothelium. In addition, H2S may prime endothelial cells (ECs) toward angiogenesis 
and contribute to wound healing, aside to its well-known ability to relax vascular smooth muscle 
cells (VSMCs), thereby reducing blood pressure. Finally, H2S may inhibit VSMC proliferation 
and platelet aggregation. Consistently, a deficit in H2S homeostasis is involved in the 
pathogenesis of atherosclerosis and of hyperglycaemic endothelial injury. Therefore, the 
application of H2S-releasing drugs or using gene therapy to increase endogenous H2S level may 
help restore endothelial function and antagonize the progression of cardiovascular diseases. The 
present article reviews recent studies on the role of H2S in endothelial homeostasis, under both 
physiological and pathological conditions, and its putative therapeutic applications. 
1.0 Endothelial structure and function 
The endothelium lines the luminal surface of the entire vascular tree and the cardiac 
chambers, where it is termed endocardium. As a consequence, the endothelium presents a rather 
broad extension (300 to 1000 m2) and weight (1.5 kg), achieving sizes comparable to other vital 
organs of the human body [1, 2]. The endothelium can, therefore, be regarded as a real “organ 
spread across the organism” [3] and, as such, not only it is important for the regulation of local 
tissue functions, but also for maintaining the whole organism homeostasis [4]. Vascular 
endothelial cells (ECs) possess a polarized architecture: their luminal membrane is directly 
exposed to hematic constituents and circulating cells, while the basolateral surface is separated 
from surrounding tissues by a glycoprotein basement membrane – the sub-endothelial basement 
– which is formed by fibronectin, laminin, and collagen and is secreted by ECs themselves [2]. 
Heterogeneity is, however, the hallmark of endothelium. ECs differ in morphology, function, and 
gene expression profile, so that even neighbouring cells from the same organ and blood vessel 
type exhibit distinct features [4]. For instance, vascular ECs may vary in size, shape, thickness 
and position of the nucleus. Albeit oriented along direction of blood flow, to attenuate the impact 
of shear stress forces on the vascular wall, microvascular ECs are rather thin (0.1 µm) and 
spindle-like, whilst their macrovascular counterparts are thicker (1 µm) and adopt a polygonal 
shape [5]. Ultrastructural differences have been described in the relative number of Weibel-
Palade bodies, endothelial specific organelles that store P-selectin and von Willebrand factor 
(vWF), and are mostly abundant in pulmonary vasculature as compared to thoracic aorta (where 
are absent) and myocardial capillaries (where are rare) [6]. Furthermore, caveolae or “small 
caves”, a subset of cholesterol and glycosphingolipid-rich Ω-like shaped invaginations of the 
plasma membrane, are most numerous in capillaries (up to 10.000 per cell) than in large conduit 
and resistance vessels [4]. The heterogeneity in caveolae distribution is exacerbated by the notion 
that they are far more enriched in lung microvasculature than in microvascular endothelium of 
brain, retina, and testes [7]. This feature is highly remarkable when considering that caveolae are 
not only involved in the transport of material across the EC barrier, but serve as a complex signal 
transduction platform translating extracellular inputs into well defined intracellular responses, 
owing to their ability to compartmentalize a myriad of signalling molecules [8, 9]. Similarly, the 
vesciculo-vacuolar organelle (VVO), a recently identified network of interconnected vesicles and 
vacuoles which provides the main transcellular pathway for macromolecule extravasation, spans 
venular endothelium from the luminal to the basolateral membrane, whereas it is absent in both 
arterioles and capillaries [10]. The most striking example of the phenotypic diversity in vascular 
endothelium is, however, provided by the presence or not of discontinuities, or “fenestrae”, 
along the cellular lining of blood vessels [5]. Continuous endothelium is typical of both arteries 
and veins, where an intact monolayer of ECs is held together by tight junctions and is anchored 
to the basal membrane. Conversely, the structure of capillary endothelium differs depending on 
the vascular bed, being tailored to meet the physiological demands of the underlying tissue. A 
continuous sheet of tight junctions-coupled ECs is characteristic of brain, retina, skin, lung and 
muscle capillaries, while the endothelium covering the inner surface of exocrine and endocrine 
gland, intestinal villi, kidney glomeruli and subpopulations of renal tubules presents 70 nm wide 
pores which are sealed by a 5 to 6 nm non-membranous diaphragm and termed fenestrae. This 
structural organization is essential to sustain elevated trans-endothelial transport and filtration 
rates [2, 5]. Finally, sinusoidal vascular districts, such as liver, spleen and bone marrow, exhibit 
larger fenestration (100-200 nm) among ECs which are devoid of diaphragm and associated to a 
poorly formed membrane basement [2, 5]. The structural heterogeneity of vascular endothelium 
may be dictated either by the extracellular microenvironment, neighbouring ECs being exposed 
to subtly different biochemical cues and biomechanical forces, or by epigenetic modifications, 
which are independent of the surrounding milieu [4]. The interaction between external factors 
and individual gene expression profile becomes evident when ECs from distinct organs are 
harvested from their native tissue and cultured in growing medium: under such “artificial” 
conditions, they undergo a phenotypic drift that dampen all their differences and is driven by 
their intrinsic genetic programme [4]. This feature complicates endothelial research, which 
requires the in vivo validation of each result obtained in vitro. 
Despite of the molecular underpinnings, the remarkable versatility in endothelial 
phenotype is reflected by the vast repertoire of signalling functions that it accomplishes all along 
the vasculature [4]. Broadly speaking, ECs exploit their strategic location at the interface 
between circulating blood and adjoining tissues to perceive the myriad of inputs incoming from 
both sources and, thereby, produce the most proper output to meet the local needs [4, 5]. This, in 
turn, exerts a profound effect on the homeostasis of the whole organism. A quiescent, i.e. not 
activated, endothelium serves as anti-coagulant and non-thrombogenic surface, by preserving 
blood fluidity and preventing platelet activation and clotting. Moreover, it holds the balance 
between vasodilators and vasoconstrictors, thereby regulating the vasomotor tone, and 
determines both para- and trans-cellular permeability by changes in the diameter of inter-
endothelial clefts and in the luminal expression of cell-adhesion receptors [5]. Vascular EC 
restores blood perfusion in hypoxic tissues and organs through the process of sprouting 
angiogenesis, which is entirely sustained by local ECs and does not require the mobilization of 
circulating endothelial progenitor cells [11, 12]. The endothelium modulates such different 
functions due to its ability to synthesize and release a number of agents that regulate vascular 
smooth muscle cell (VSMC) contractility, trigger inflammatory processes, and affect 
haemostasis [5, 13]. Among the vasodilators produced by ECs are nitric oxide (NO), prostacyclin 
(PGI2), carbon monoxide (CO), hydrogen sulfide (H2S), epoxyeicosatrienoic acids (EETs), and 
adenosine [13-15], while vasoconstrictors include endothelin-1 (ET-1), angiotensin II (Ang II), 
thromboxane A2, prostaglandin H2 (PGH2), and reactive oxygen species (ROS) [14, 16]. 
Furthermore, ECs communicate with VSMCs via myoendothelial gap junctions or humoral 
factors to induce endothelium-dependent hyperpolarization (the so-called endothelium-
dependent hyperpolarizing factor, EDHF) caused by the opening of SKCa and IKCa channels 
(small and intermediate conductance Ca2+-activated K+ channels, respectively) [17], thereby 
attenuating the vascular tone [18] . The inflammatory response is modulated by H2S and NO 
liberation or by expressing a number of proteins involved in leukocyte adhesion, rolling, and 
extravasation, including intercellular adhesion molecule-1 (ICAM-1), vascular adhesion 
molecule-1 (VCAM-1), E-selectin, P-selectin, and junction adhesion molecule-1 [5]. 
Endothelial-derived H2S and NO serve an additional role within the vascular wall by inhibiting 
VSMC proliferation and migration [13], thereby preventing the pathological remodeling of blood 
vessel structure (see below). ECs regulate coagulation and fibrinolysis by secreting a variety of 
mediators, such as plasminogen activator, tissue factor inhibitor, von Willebrand factor, NO, 
thromboxane A2, plasminogen-activator inhibitor-1, and fibrinogen [19]. Additionally, vascular 
ECs might behave as thermo-sensors and determine peripheral vasoconstriction or vasodilation 
according to the environmental temperature [20]. A more careful inspection of EC signaling, 
however, discloses that not all vascular ECs fulfill the same functions, and that some branches of 
the vascular bed are more prone to carry out a specific task than others. Alternatively, the same 
process may be regulated through diverse mechanisms by the endothelia of two different 
vascular districts [4, 5]. For instance, H2S relaxes small mesenteric arteries much more potently 
than aortic tissues [21]. NO is the main vasodilator released by ECs in arteries, such as aorta, 
coronary and brain arteries while EDHF is far more important in smaller arteries and resistance 
vessels [22]. The identity of EDHFs may vary depending on the vessel type, EETs serve as 
EDHF in peripheral muscular and subcutaneous arterioles and H2O2 in mesenteric arteries [23]. 
Another case in point for the functional heterogeneity displayed by vascular endothelium is the 
leukocyte migration across the vascular wall. The trafficking of white blood cells takes place 
primarily in post-capillary venules, which also provide the main sites for inducible permeability 
during acute and chronic inflammation [5]. Angiogenesis is a typical feature of the capillary 
network all along the vasculature, whilst arteries and veins are unable of sprouting novel vessels 
towards adjacent hypoxic tissues [24]. However, the wall of arterial conduits contains a complete 
hierarchy of proliferating cells, ranging from highly replicating clones to non-dividing cells, 
which are absent in narrower vessels [25]. These cells are those most likely recruited upon a 
traumatic injury to restore endothelial integrity when the extent of the lesion is limited to a small 
EC strip [8]. Therefore, endothelium has been described as an input-output device, which utilizes 
an intricate and non-linear arrays of signal transduction pathways to continuously translate the 
host of extracellular stimuli detected by its membrane receptors into a specific cellular behaviour 
(e.g. NO synthase, EDHF production, cytoskeletal rearrangement) or phenotype (e.g. 
proliferation or migration). The delicate balance between vasodilation and vasoconstriction, 
thrombogenesis and fibrinolysis, prevention and stimulation of platelet activation, inhibition and 
promotion of VSMC proliferation and migration, must be finely tuned to maintain vascular 
homeostasis at both local and systemic level. As a consequence of the architectural organization 
of peripheral circulation, ECs indeed establish an intimate relationship (5 µm or less, which is 
the average distance between ECs and the closest tissue or cells- when peripheral circulation 
restricts to the narrower and more densely packed capillary tubes) with cells that have direct 
contact with ECs of the whole organism. Any significant loss in endothelial integrity leads to a 
loss of function, whereas the hyper-activation of EC signalling results in abnormal function, both 
being detrimental for the whole body homeostasis and collectively termed as “endothelial 
dysfunction”. Due to the structural and functional diversification in vascular endothelium 
described above, these alterations in the innermost lining of vascular wall will produce highly 
site-specific pathological conditions. 
 
2.0 Endothelial dysfunction 
One form of endothelial dysfunctions is EC detachment from the vascular wall, as 
observed upon balloon catheter angioplasty, intracoronary stent deployment and coronary artery 
bypass surgery [8, 12]. The de-endothelialisation of arterial vessels exposes the thrombogenic 
sub-endothelial matrix, thereby inducing platelet activation and aggregation at the site of lesion 
[1]. Moreover, the following drop in NO and H2S bioavailability stimulates VSMCs to switch 
from a contractile quiescent to a proliferative (synthetic) motile phenotype. As a consequence, 
VSMC migrate from the media towards the inner surface of the vessel, where they continue to 
proliferate and secrete extracellular matrix proteins, leading to neointimal tissue formation [26]. 
The consequent thickening of the vascular wall, which has been termed in-stent restenosis (ISR), 
perturbs blood supply to vital and peripheral organs and dramatically affects cardiovascular 
homeostasis [26]. Another form of  endothelial dysfunctions is caused by hyper-activation of EC 
by a variety of risk factors, including hypercholesterolemia, aging, hypertension, turbulent blood 
flow, smoking, type I and type II diabetes, glycaemia, and hyperhomocysteinemia, etc [1]. The 
endothelial sheet reacts to such abnormal environmental conditions by enhancing the production 
of ROS, among which are ONOO- and -OH, with the consequent increase in the oxidative stress 
within the vascular wall. The accompanying elevation in lipid permeability causes the 
accumulation of low density lipoprotein (LDL) in the sub-endothelial space, where they are thus 
oxidized to oxLDL [27]. At the same time, vascular ECs are induced to express increased 
amounts of adhesion molecules (P-selectin and E-selectin) and integrins (ICAM-1 and VCAM-
1), which encourage leukocyte adhesion to the vessel wall and their subsequent translocaiton into 
the intimal layer. This process is favoured by the chemotactic activity of oxLDL and by the 
reduced bioavailability of NO [1], or H2S [28]. Once recruited into the nascent atheromatous 
lesion, monocytes-derived macrophages ingest oxLDL to become foam cells and to form fatty 
streaks within the artery wall [27]. Foam cells, in turn, release a number of inflammatory 
mediators and cytokines which induce the phenotypic switch in the neighbouring VSMCs as part 
of the pathogenic process of plaque formation [27]. This structural remodelling of the vascular 
wall significantly narrows arterial lumen, thereby causing a stenosis which may lead to local 
ischemia if the limitation to blood supply is too severe. The vasospasms determined by the shift 
towards constricting mediators released by dysfunctional ECs exacerbate tissue injury and 
eventually aggravates the acute consequences of the atherosclerotic process [29]. The pathologic 
significance of  the improper activation of EC signalling is further underscored by the growing 
number of disorders consequent to excessive blood vessel growth, such as cancer, infantile 
haemangioma, age-related macular degeneration, pulmonary hypertension, rheumatoid arthritis, 
peptic ulcer and psoriasis [30, 31]. Among the others, tumoral angiogenesis is drawing particular 
attention owing to the failure of the most commonly employed targeted therapies to improve 
overall survival (OS) or progression-free survival (PFS) beyond a few months and to prevent 
subsequent relapse of the malignancy [12, 32]. Microscopic lesions remain quiescent until they 
reach to a clinically detectable size (1-2 mm3), afterword they spread to distant organs and, 
eventually, kill the host in the absence of a functional vascular network supplying oxygen and 
nutrients, removing the catabolic waste, and providing the access to peripheral circulation. The 
hypoxic environment typical of a growing tumour is sensed by neoplastic cells, where the drop in 
O2 tension activates the hypoxia-inducible factor-1α (HIF1α), a transcription factor that controls 
the expression of vascular endothelial growth factor (VEGF). VEGF is then released in the 
surrounding tissues to induce adjoining capillaries to sprout towards the micrometastatic tumor, 
thus pawing the way for its connection to systemic vasculature and progression to a 
macrometastatic, invasive phenotype [33]. In addition, VEGF activates bone marrow-residing 
endothelial progenitor cells (EPCs) to emerge from the vascular niche, traffic to the tumour site, 
and physically engraft within vessel lumen [12, 34]. The most common targeted therapies aim at 
interfering with the signal transduction pathways downstream VEGFR-2, the receptor isoform 
whereby VEGF exerts its pro-angiogenic action on both mature ECs and endothelial committed 
progenitors [32, 35].  
These lines of evidence hint at vascular endothelium as the main actor in many human 
pathologies, portraying either as a victim of  iatrogen  interventions or as the primary inducer of 
human disease [36]. Targeting at a dysfunctional endothelium might suppress/activate the 
up/down-regulated EC-dependent process in the diseased vessel, but bear the risk to perturb the 
otherwise normal vasculature in nearby or more remote normal organs. For instance, promoting 
therapeutic angiogenesis to rescue blood supply to ischemic limbs in peripheral arterial disease 
(PAD) and to the insufficient heart in coronary artery disease (CAD) might lead to the unwanted 
vascularisation of dormant micrometastasis and subsequent tumour progression. Therefore, any 
pharmacological approach aiming to restore the proper endothelial signalling should be carefully 
designed to selectively interfere with the dysfunctional molecular pathway(s) 
and camouflage among the myriad of endothelium-released mediators in order to avoid any 
undesired off-target effects "in" and avoid any undesired off-target effects. It is, therefore, not 
surprising that gasotransmitters stand out among the most promising tools in the clinical practice 
due to their ability to rescue the endothelial phenotype without grossly altering the normal 
functioning of healthy vessels.  
 3. Hydrogen sulfide (H2S) production and signaling in Endothelium  
Vascular ECs produce H2S by cystathionine ɣ-lyase enzyme (CSE, E.C 4.4.1.1) [15, 37], 
which is the major H2S synthesizing enzyme found in endothelium [38].  CSE is distributed 
within the cytosol and requires pyridoxal-5′-phosphate (vitamin B6) as co-factor [38]. Two major 
substrates utilized by CSE to produce H2S are cysteine and homocysteine [38, 39]. CSE 
expression is regulated by the transcription factor specificity protein-1 (Sp1) [40-42]. In the 
vessels, Sp1 regulates CSE expression during VSMC phenotypic switch from a differentiated 
state (contractile phenotype) to a dedifferentiated one (synthetic phenotype) [42]. MicroRNA-
21 (miR-21) repressed CSE mRNA translation and protein expression in human aortic VSMCs 
by directly targeting at SP1 3’-untranslated regions [41]. MiR-21 overexpression inhibited CSE 
and SP1 expressions and H2S production, stimulated VSMC proliferation, and reduced VSMC 
differentiation genes expression [41]. Similarly, knockdown of Sp1 and Elk1 blunted CSE 
expression in pancreatic beta cells [40]. The contribution of Sp1 to CSE expression in vascular 
ECs remains, however, to be elucidated. One study has reported that CSE protein can be S-
sulfhydrated when liver lysates treated with 100 µM Sodium Hydrosulfide (NaHS) were 
subjected to LC-MS/MS [43]. A rrecent study also showed that exogenous H2S treatment can 
modulate CSE expression in a dose-dependent fashion: downregulation with 10-80 µM H2S, 
upregulation with 120 µM, then full inhibition with higher than 160 µM [44].  
H2S stimulates the phosphorylation of many signaling proteins in ECs isolated from 
different vascular beds and animal species. For example, treatment with NaHS (10 - 200 µM) 
stimulated Akt phosphorylation in retinal EC line RF/6A [45]. Treatment with NaHS 60 µM 
promotes Akt, MAPK kinases ERK, p38 and hsp27 phosphorylation in human umbilical vein 
ECs (HUVECs) [46]. NaHS (50 - 100 µM) stimulated eNOS phosphorylation in primarily 
isolated mouse ECs and EAy-926 cells [47]. Treatment of aortic rings with NaHS enhanced 
phosphorylation on Ser-239 of the vasodilator-stimulated phosphoprotein (VASP) [48]. The 
molecular mechanisms for H2S-induced phosphorylation remain unclear and require further 
investigation. 
S-sulfhydration is proposed to be the main mechanism for H2S bio-signaling as shown in 
Figure. 1 [43]. S-sulfhydration is now an established post-translational modification mechanism 
in which H2S modifies cysteine residue of protein by converting sulfhydryl group (-SH) of 
cysteine to  -SSH group [43]. H2S sulfhydrates many proteins in different tissues or cells to 
maintain their physiological functions.  For example, in liver alone about 10 to 25% of expressed 
proteins are sulfhydrated under physiological conditions [43]. Among prominent sulfhydrated 
proteins in liver were glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-tubulin, and 
actin [43]. S-sulfhydration of these proteins elicits a seven-fold increase in GAPDH activity, 
enhances actin polymerization and reveals rearrangement of the cytoskeleton [43]. Furthermore, 
several recent studies have demonstrated the physiological role of sulfhydration modification in 
multiple cell types. For instance, H2S-induced S-sulfhydration of ATP-sensitive potassium 
(KATP) channels hyperpolarizes VSMCs and induces relaxation of the vascular tissues [49]. S-
sulfhydration of intermediate (IKCa) and small conductance (SKCa) calcium-activated potassium 
channels hyperpolarizes vascular ECs and induces endothelium-dependent VSMC 
hyperpolarization [50]. S-sulfhydration of nuclear factor κB (NF-κB) physiologically determines 
its anti-apoptotic transcriptional activity [51]. S-sulfhydration of protein tyrosine phosphatases 
(PTP1B) alters endoplasmic reticulum stress response in HEK-293T cells [52]. H2S-induced S-
sulfhydration of Kelch-like ECH-associated protein 1 (Keap1) attenuates oxidative stress and 
delays cellular senescence in mouse embryonic fibroblasts cells [53]. H2S induces S-
sulfhydration of parkin and enhances E3 ligase activity [54]. Collectively, these studies show 
that H2S sulfhydrates a large number of proteins in different tissues, and most of them are 
sulfhydrated under basal levels.  
 
4. Nitric oxide (NO) production and signaling in ECs 
NO production in ECs is catalyzed by endothelial nitric oxide synthase (eNOS, 
EC1.14.13.39) [55]. The eNOS enzyme utilizes L-arginine as substrate to generate NO from the 
terminal guanidine nitrogen, thereby producing L-citrulline [55]. The eNOS isoform was first 
purified from bovine aortic ECs (BAECs) [56], primarily localized in particulate subcellular 
fraction, and found enzymatically active when associated with the plasma membrane [57]. In 
vascular wall, the expression of eNOS is predominantly restricted to endothelium, whilst it can 
be detected in cardiomyocytes, hepatocytes, thrombocytes, VSMCs and lung epithelial cells [58]. 
In the endothelium, eNOS is constitutively expressed and display common features with 
housekeeping or constitutively expressed gene promoters, such as the truancy of a TATA box 
and many SP-1 sites [59]. The location of SP-1 binding sites near the starting site for the 
transcription or other putative binding domains suggests that it may be regulated by a variety of 
transcription factors-mediated signals [59]. In addition, different stimuli have the ability 
modulate eNOS expression [59-61]. For example, shear stress modulates eNOS expression in 
cultured ECs and intact arteries [61, 62]. Estrogen modulates both eNOS expression and 
phosphorylation in ECs [63]. Insulin treatment (10−10 to 10−7 mmol/L) causes a time-dependent 
(2-8 hrs) increase in the expression of eNOS mRNA and protein level in BAECs [64]. Glucagon-
like peptide 1(9-36) enhanced the activity and expression levels of eNOS in HUVECs [65].  
Post-translational modifications, such as phosphorylation and S-nitrosylation, are 
common mechanisms for eNOS regulation as shown in Table 1 [66]. These modifications can be 
induced by physiological or pathophysiological stimuli, to inhibit or stimulate eNOS enzyme 
activity [55]. For example, phosphorylation of eNOS at Ser-114 inhibits eNOS activity [67]. 
Conversely, the phosphorylation of eNOS at Ser-617 and Ser-635 activates eNOS [68]. 
Phosphorylation eNOS at Ser-1177/Ser-1179 (human/bovine) activate eNOS [69]. eNOS de-
phosphorylation of Thr-495 activates eNOS [70]. Phosphorylation of Try-81 and Try-567 
appears to modulate eNOS activity [71]. 
 NO can modify many proteins by S-nitrosylation, including eNOS itself, thereby 
inhibiting eNOS activity [72]. De-nitrosylation increases eNOS activity [72]. Consistently, 
eNOS has been found to be basally S-nitrosylated in BAECs, where it is activated by the de-
nitrosylation brought about by agonists, such as VEGF and insulin [73]. The eNOS isoform also 
presents unique posttranslational modification features among the three known NOS isoforms, 
being acylated by both the fatty acids myristate and palmitate [74-76]. Other posttranslational 
modifications can modulate eNOS, such as palmitoylation which occurs at cysteine residue, and 
myristoylation which occurs at glycine. These modifications affect the subcellular distribution of 
the eNOS enzyme [77]. Palmitoylation is an irreversible protein modification, whereas 
myristoylation is reversible and might take place in random sequences [78]. 
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NO 
 
H2S and NO 
 
Modification type 
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modification 
 
Non-catalyzed 
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modification 
 
Enzyme driven 
 
Effect on enzyme 
activity 
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depending on the 
phosphorylated site 
 
 
Reversible 
mechanism 
 
 
Not known 
 
 
Reversible: i.e 
Thioredioxine, 
GSNO reductase 
 
Reversible: i.e 
Phosphatases 
 
 
Energetic 
mechanism 
 
No ATP needed 
 
No ATP needed 
 
Bio - energetic and need 
ATP 
 
 
Bond-dissociation 
energy 
 
 
60 kcal/mole 
 
12 - 20 kcal/mole 
 
5 kcal/mole 
 
 
Detection method 
 
 
Modified biotin switch 
assay/ Immunoblot, LC 
MS/MS 
 
 
Biotin switch 
assay + Ascorbate, 
LC MS/MS 
 
 
Phsopho-specific 
antibody/ Immunoblot 
 
Known modified 
proteins 
 
GAPDH, actin, eNOS 
 
GAPDH, Akt, 
eNOS 
 
Akt, ERK1/2, p38, eNOS 
 
Bond 
 
Hydropersulfide (-SSH) 
 
S-nitrosothiol (-
SNO) 
 
Phosphate  (-PO43-) 
 
 
Amino acid 
residue 
 
Cysteine 
 
Cysteine 
 
Serine, theronine, alanine 
 
 
 
Modification    
Table 1.   Summary of posttranslational modification effects of H2S and NO in ECs 
As mentioned above, NO can regulate many cellular functions through S-nitrosylation 
[79]. S-nitrosylation consists of the modification of cysteine thiols (-SH) by NO to form S-
nitrosothiols (SNOs) [80]. This process influences protein function and protein-protein 
interaction in different types of tissue [80]. Several endothelial proteins can be S-nitrosylated 
under physiological and pathological conditions. For instance, statins stimulate thioredoxin S-
nitrosylation, which enhances its enzymatic activity and significantly dampens intracellular ROS 
levels in HUVECs [52]. SNP  (1-2 mM) induces extracellular signal-regulated kinases (ERK) S-
nitrosylation in MCF-7 breast cancer cells [81]. GSNO treatment  (1 mM) stimulated p53 
(protein 53) phosphorylation in NIH/3T3 cells [81]. Not all cysteines with free-thiol have the 
ability to become S-nitrosylated [82]. Several factors were proposed to be involved in cysteine 
reactivity, such as thiol nucleophilicity (pKa), presence of an acid-base motif nearby the cysteine 
residue, local pH, redox tone and divalent cations, i.e. Mg2+ or Ca2+ [79, 83]. However, the exact 
molecular mechanism to determine which or how cysteine becomes S-nitrosylated is still 
unclear. Cysteine de-nitrosylation is the reversible mechanism of S-nitrosylation accomplished 
by two enzyme systems, i.e. S-nitrosoglutathione reductase (GSNOR) and thioredoxin (Trx) [84, 
85]. GSNOR is involved in SNO removal through metabolism of S-nitrosoglutathione [84]. Trx 
is a 12 kDa protein which has an active site with two redox-active cysteine residues (Cys-Gly-
Pro-Cys) [86]. This site binds to SNO (Trx-SNO) through a disulfide bridge and removes SNO 
groups [86].   
 
 Figure 1. Production and signaling mechanisms of H2S and NO in ECs 
 
5. CSE and eNOS knockout mice models  
A CSE-knockout mouse (CSE-KO) was first generated in 2008 [37]. The deletion of cse 
gene led to significant suppression of endogenous H2S production [37].  The levels of H2S in 
aorta and heart of homozygous CSE-KO mice are reduced by about 80% with a 50% reduction in 
heterozygous CSE-KO mice [37]. Likewise, H2S levels in serum of homozygous and 
heterozygous CSE-KO mice are reduced by 50% and 20%, respectively [37]. CSE is the main 
H2S producing enzyme in the vascular system [37].  As a consequence, CSE-KO mice developed 
hypertension with an onset at 8 weeks of age [37]. Moreover, small resistance arteries displayed 
a significant reduction in endothelium-dependent vasorelaxation [37]. Aortic rings isolated from 
CSE-KO mice exhibited markedly reduced neovascularization in response to VEGF treatment 
when compared to wild-type littermates. Wound healing was also delayed in CSE-KO mice [46]. 
cGMP levels in the aorta, mesenteric artery and plasma of CSE-KO mice were significantly 
lower than those from wild-type littermates [48]. Similar to CSE-KO mice, eNOS-knockout mice 
(eNOS-KO) have been developed as well [87]. These animals lack eNOS mRNA and NOS 
enzymatic activity, but were fertile and displayed normal anatomy [87, 88]. The phenotypic 
changes caused by eNOS inactivation include lack of endothelium-derived relaxing factor 
(EDRF) activity and consequent hypertension [87, 88], an increase in VSMC proliferation [89], 
platelet aggregation [90], and in leukocyte-endothelial adhesion [91], abnormalities in 
mitochondrial function and biogenesis [92], insulin resistance [93], and a higher risk to undergo 
severe strokes [94] and develop atherosclerosis [95]. Up to our knowledge, CSE/eNOS double 
knockout (DKO) has not been established. Without doubt, developing eNOS/CSE-DKO mice 
will provide a great animal model to examine the combined effects of H2S and NO in vascular 
ECs.  
 
6. Pathophysiological and physiological function of H2S in ECs 
The NO-H2S balance plays a pivotal role for many pathophysiological and physiological 
events in the vascular system and contributes to initiation and progression of several forms of EC 
dysfunction, as shown in Figure 2. Here we briefly reviewed the roles of H2S and NO in 
regulation of different EC functions, and their precise role in diseases related to EC dysfunction.  
 
 
 
 
  
Figure 2.  H2S and NO maintain different EC functions 
6. 1. The roles of H2S and NO in vasodilation  
H2S released from NaHS, dilates blood vessels both in vitro and in vivo, albeit distinct 
vascular beds display different sensitivities to the gasotransmitter [15, 38]. The vasorelaxing 
action of NaHS, administrated at concentrations ranging from 50 µM to 100 µM, has been 
observed in rat aorta and hepatic artery [96, 97], as well as in resistance mesenteric arteries [21], 
gastric artery and gastric mucosal circulation [98], cerebral arterioles and artery [99, 100], 
pulmonary artery [101], and coronary artery [102]. Since NaHS is five-to-nine fold more potent 
in relaxing mesenteric arteries than thoracic aorta and pulmonary artery (EC50 25 µM vs. 125 µM 
and 233 µM, respectively), it has been proposed as a key regulator of peripheral resistance 
arteries and, therefore, of blood pressure [15]. H2S has been shown to dilate other isolated 
mammalian blood conduits in vitro, such as human internal mammary artery [103], mouse aorta 
and ear microcirculation [104, 105], and newborn pig cerebral arterioles [106]. Consistent with 
these data, the systemic injection of NaHS at 10-50 µM kg-1 causes a transient decrease in mean 
arterial pressure (MAP) in vivo by 12-40 mmHg [96, 107, 108], whereas GYY4137 (26-133 µM 
Kg-1), a slow H2S-releasing donor, produces a slowly developed fall in MAP that persists long 
after drug administration [108]. These observations have been corroborated by the CSE-KO 
mouse model. CSE-KO mice develop an age-dependent hypertension starting at 8 weeks of age, 
and peaked at 12 weeks [37].  This significant elevation in blood pressure is associated with the 
lack of H2S leading to reduced endothelium-dependent relaxation and elevated resting membrane 
potential of VSMCs [37], but not those of aorta [17]. These observations are compatible with the 
notion that H2S serves as an EDRF [109]. It has been proposed that acetylcholine activates CSE 
in a Ca2+/CaM-dependent manner in ECs [32, 110]. Once produced, H2S diffuses to the 
adjoining VSMCs, where it activates KATP channels, promoting membrane hyperpolarization and 
reducing vascular tone by counteracting the activation of voltage-gated Ca2+ channels [96, 109]. 
H2S may also act as an EDHF. As recently shown in the mesenteric arteries of CSE-KO mice, 
H2S causes endothelium-dependent hyperpolarization of VSMCs by stimulating intermediate- 
and small-conductance KCa (IKCa and SKCa) channels [17, 50]. H2S has been suggested to mimic 
NO effect on cGMP level but through different mechanisms.  While NO stimulates cGMP 
production, H2S decreases cGMP degradation by inhibiting phosphodiesterase-5 (PDE-5) 
activity in VSMCs, which leads to vasorelaxation in a PKG-dependent manner [48, 111, 112]. In 
primariy aortic ECs isolated from WT mice, H2S activates the PI-3K/Akt signaling pathway 
following increased eNOS phosphorylation in Ser-1177, thereby increasing NO production [47]. 
Likewise, NO-induced cGMP accumulation and vasorelaxation were attenuated by the genetic 
knockout of CSE [113], suggesting that both gasotransmitters may act on cGMP to reduce blood 
pressure.  
 
6. 2. The roles of H2S and NO in apoptosis  
H2S affects programmed cell death, or apoptosis, in a cell-specific manner. For instance, 
NaHS has been shown to prevent apoptosis in neurons, cardiomyocytes, colon cancer cells, and 
3T3 fibroblasts at concentrations lower than 300 µM [15]. The anti-apoptotic action of H2S is 
related to its capability to prevent the mitochondrial membrane potential dissipation by the 
activation of multiple mechanism, but all through KATP channels [15]. On the other hand, H2S 
stimulates VSMC apoptosis [114]. The increased endogenous production of H2S derived from 
CSE overexpression induces apoptosis in human VSMCs by activating ERK1/2 and capsase-3 
[114]. Interestingly, VSMCs isolated from CSE-KO mice were more susceptible to apoptosis 
induced by exogenous H2S at 100 µM. The pro-apoptotic effects of H2S are mediated by the 
phosphorylation of ERK1/2 and expression of cyclin D1 and p21 (Cip/WAF-1) [115]. As for 
vascular endothelium, NaHS pretreatment has recently been demonstrated to decrease SA β-gal 
(cell senescence-associated β-galactosidase) positive rate and cellular apoptosis in HUVECs 
[116]. Similarly, NaHS triggers an anti-oxidative stress mechanism which protects primary 
HUVECs from apoptosis challenged with high glucose [117]. The anti-apoptotic action of H2S in 
macrophages is mediated by S-sulfhydration of NF-kB [51]. H2S sulfhydrates the p65 subunit of 
NF-κB at cysteine-38, which promotes its binding to the co-activator ribosomal protein S3 
(RPS3) [51].  H2S inhibits NO production, iNOS gene expression and NF-κB activation in LPS-
stimulated macrophages cells via a mechanism involving the action of heme oxygenase-1 (HO-
1) and CO [118]. Finally, the pro-apoptotic or anti-apoptotic effects of NO depends on the 
concentration of NO employed, i.e. nanomolar range affects Akt phosphorylation and hypoxia 
inducible factor (HIF)-1α stabilization (pro-survival pathways) and prevent apoptosis, whereas 
micromolar range triggers phosphorylation of p53 and induces apoptosis [119]. 
 
6. 3. The roles of H2S and NO in oxidative stress 
H2S is a strong reducing agent and may easily interact with oxidative species [15]. 
Several studies have shown that H2S displays anti-oxidant activity at 10 - 100 µM [107, 120, 
121]. H2S protects the luminal surface of blood vessel from oxidative stress caused by 
ischemia/reperfusion injury, as well as from development of atherosclerotic lesions, [28, 122]. 
H2S rescues CSE-KO mice from the injury and mortality associated with renal ischemia. 
Moreover, CSE overexpression reduces the amount of reactive oxygen species (ROS) produced 
during stress in renal tissues [122]. NaHS has been shown to mitigate the methionine-induced 
production of free radicals in brain ECs (bEnd3) and to enhance the inhibitory action of reduced 
glutathione (GSH), catalase (CAT), superoxide dismutase (SOD) and L-NAME on ROS 
production [123]. Herein, 10 - 500 µM NaHS preserves mitochondrial function by reducing the 
deleterious effects of oxidative stress on the antioxidants enzymes, SOD, catalase, glutathione 
peroxidase and glutathione-S-transferase [124]. Furthermore, H2S delays EC senescence by 
attenuating oxidative stress [116]. A study shows that late passage (e.g. 12) HUVECs have lower 
SOD activity and higher H2O2 level as compared with younger HUVECs (e.g. 4), whereas NaHS 
pretreatment reverses the changes in SOD activity and H2O2 level [116]. Similarly, the 
expression levels of both xanthine oxidase (XOD) and subunits p67 (phox) of NADPH oxidase 
are increased in the senescent group relative to the fresh one, whereas manganese-superoxide 
dismutase (Mn-SOD) expression levels are decreased [125]. NaHS treatment results in the up-
regulation of both XOD and p67 (phox) levels but down-regulation of Mn-SOD expression 
[116], thereby slowing down cell aging. Another study shows that H2S delays HUVEC 
senescence and prevents H2O2-induced damage via sirtuin 1 activation [125]. In addition, H2S-
releasing drugs, NaHS and ACS6 (both at 10 µM), inhibit superoxide formation and gp91 (phox) 
(a catalytic subunit of NADPH oxidase) expression in porcine pulmonary arterial ECs by 
increasing cAMP levels and recruiting PKA upon the inhibition of PDE-5 [126]. The 
cytoprotective effect of H2S in ECs might involve an increase in the intracellular levels of GSH, 
one of the most abundant and effective components of the defense system against free radicals 
[127]. Studies conducted on mouse embryonic fibroblasts isolated from CSE-KO mice (CSE-
KO-MEFs) show an increase in oxidative stress and acceleration in cellular senescence 
compared with MEFs isolated from wild-type mice [127]. Incubation of CSE-KO-MEFs with 
NaHS significantly increases GSH levels and rescues KO-MEFs from senescence [127]. H2S S-
sulfhydrates Keap1, which regulates the antioxidant response, thereby inhibiting Nrf2 activity 
[127]. S-sulfhydration of Keap1 at cysteine-151 induces Nrf2 dissociation from Keap1, thus 
enhancing the nuclear translocation of Nrf2 and increasing mRNA levels of Nrf2-targeted 
downstream genes, such as glutamate-cysteine ligase and glutathione reductase [127]. In 
addition, H2S scavenge ONOO- and suppress tyrosine nitration in VSMCs in the presence of 
homocysteine (Hcy) [128]. The anti-oxidant properties of H2S could therapeutically be exploited 
to prevent lung endothelium damage caused to by oxygen therapy [129], particulate air pollution 
or tobacco smoke [130]. Similarly, regulation of NO production during conditions of oxidative 
stress is very important for cell survival. Previous studies have shown that increased oxidative 
stress is often associated with decreased NO levels [131]. Additionally, as mention before, NO 
generation together with increased superoxide generation, leads to elevated peroxynitrite 
formation, which is a powerful oxidant, and related to oxidative injury of blood vessels [131]. 
 
6. 4. The roles of H2S and NO in inflammation 
The vascular protective action of H2S involves its anti-inflammatory effects on the 
innermost lining of blood vessels. H2S, released from either NaHS (10-100 µM) or S-propargyl-
cysteine (SPRC; 1-10 µM), a novel sulphur-containing amino acid, inhibits the expression of 
adhesion molecules, including ICAM-1, VCAM-1, P-selectin, and E-selectin, induced by pro-
inflammatory cytokines, such as tumour necrosis factor-α (TNF-α), in HUVECs [132, 133]. H2S 
prevents the complication of non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic 
acid (ASA) therapy [134].  H2S attenuates gastric mucosal injury, TNF-α, ICAM-1 in rat 
mesenteric venules challenged with ASA or NSAIDs [134]. Conversely, pharmacological 
blockade of CSE with β-cyanoalanine (BCA) enhanced leukocyte adhesion and rolling [135]. In 
agreement with these data, carrageenan-induced paw oedema is suppressed by either NaHS 
(EC50 = 35 µM Kg-1) or Na2S (EC50 = 28 µM Kg-1) and boosted by BCA [134]. The anti-
inflammatory action of H2S involves the activation of KATP and BKCa channels [134, 136] and 
the up-regulation of HO-1 [133], as well as the inhibition of p38 and NF-kB signalling pathways. 
Furthermore, H2S hampers TNF-α-induced monocyte-endothelial interactions by down-
regulating the expression of the monocyte chemo-attractant protein-1 (MCP-1) through the 
inhibition of disintegrin and metalloproteinase metallopeptidase domain 17 (ADAM17) [137]. 
The ADAM17-dependent TNF-converting enzyme (TACE) activity is, in turn, essential for 
soluble TNF-α shedding and up-regulation of MCP-1 levels in HUVECs [137]. NaHS 
administration at 100 µM kg-1 restores gastric microcirculation in a KATP channels-dependent 
manner [134]. NO also plays a key role in the pathogenesis of inflammation as an anti-
inflammatory mediator under normal physiological conditions. On the other hand, NO is 
considered as a pro-inflammatory mediator that induces inflammation due to over production in 
abnormal situations [138]. Finally, NO inhibits adhesion of inflammatory cells to the endothelial 
surface as well [139]. 
 
6. 5. The roles of H2S and NO in angiogenesis 
H2S has recently been recognized as an important regulator for angiogenesis both in vitro 
and in vivo under physiological conditions [46, 140]. Silencing of CSE gene reduces migration 
and sprouting of HUVECs in vitro [46]. In agreement with these data, the BrdU assay disclosed 
that the proliferation rate of primarily isolated ECs was dramatically suppressed by knockdown 
of CSE, but restored by exogenously H2S treatment [47]. Moreover, ex vivo mice aortic ring 
angiogenesis assay reveals a marked decrease in neovascularization when the aortic tissue from 
CSE-KO mice was cultured in vitro [47]. Conversely, NaHS promotes blood vessel growth of 
aorta tissues from both WT and CSE-KO mice [47]. Intraperitoneal administration of NaHS for 7 
days at 10 - 50 mmol·kg-1·day1 increases neovascularization in the mouse in vivo [45]. 
Consistently, treatment with Na2S increases the vascular length in chicken chorioallantoic 
membranes (CAMs) at doses of 0.24 - 240 pmol/egg [45]. Blockade of CSE with PPG for 48 hr 
at increasing concentrations (3, 30, and 300 µmole/egg) decreases vascular network length and 
branching of CAM [46]. NaHS at a concentration of 100 µmol·kg-1·day-1 restores blood 
perfusion in a rat model of hindlimb ischemia by promoting local vessel growth [140]. 
Therapeutic angiogenesis of occluded peripheral arteries has also been reported in C57BL/6J 
mice supplemented with Na2S at 0.5 mg/kg and 1 mg/kg [141]. Likewise, NaHS (30 µM/l in 
drinking water for 4 weeks) attenuates cardiac remodeling involve in chronic heart failure by 
promoting in vivo angiogenesis in a rat model of myocardial infarction [142]. The signal 
transduction pathways underlying the pro-angiogenic role of H2S are not fully unraveled [13, 
47]. Activation of PI-3K/Akt by H2S has been shown to regulate tube-like structure formation in 
the retinal EC line (RF/6A) by inducing the up-regulation of the adhesion molecules, integrin α2 
and β1, and survivin [45]. H2S increases Akt phosphorylation and improves regional blood flow 
in a rat  model of unilateral hindlimb ischemia [140]. Mitogen-activated protein kinases (MAPK) 
and ERK1/2 are not activated by H2S in RF/6A cells [45], but the activation of MAPKs, such as 
ERK1/2 and p38, by H2S was shown to play a key role in HUVEC migration [46]. The use of 
different concentrations of H2S donors, of multiple EC types, and of diverse assay systems could 
explain the heterogeneity observed in the molecular underpinnings of the pro-angiogenic effects 
of H2S. Importantly, the KATP channel blocker glibenclamide abolished H2S-induced p38 
phosphorylation and HUVEC motility [46]. Therefore, it can be argued that KATP channels are 
located upstream of MAPKs in the signaling pathway contributing to H2S-induced angiogenesis. 
Another putative mechanistic link between H2S and the molecular decoders of its pro-
angiogenic effect is the increase intracellular Ca2+ concentration ([Ca2+]i) [13, 143]. In fact, many 
studies have provided the evidence that NaHS affects intracellular Ca2+ signals in a variety of 
ECs, such as human saphenous vein ECs [144], human microvascular dermal ECs (HMVECs) 
[145], and rat aortic ECs (RAECs) [146]. The Ca2+ response to NaHS in human ECs is shaped by 
the interaction between intracellular Ca2+ release from the endoplasmic reticulum reservoir, 
which is mainly mediated by inositol-1,4,5-trisphosphate (InsP3) receptors, and store-operated 
calcium entry (SOCE) across the plasma membrane [144]. Conversely, Ca2+ inflow patterned 
H2S-evoked elevations in [Ca2+]i in both HMVECs and RAECs [13, 145]. Ca2+ entry in rat aortic 
endothelium is supported by the reverse mode of the Na+/Ca2+ exchanger (NCX) and sustained 
by KATP channels-dependent membrane hyperpolarization [146].  
Similar to vasorelaxation, NO may be involved in the pro-angiogenic action of H2S [112] 
Accordingly, pharmacological blockage of protein kinase G  (PKG) prevented H2S-induced 
bEnd3 proliferation and migration in vitro, whereas NaHS-elicited neo-vascularization of 
Matrigel plugs in vivo was absent in eNOS-KO mice [113]. In addition, CSE deficiency 
abolished the pro-angiogenic role of NO donors both in vitro and in vivo [47]. Treatment with 
either L-NAME or siRNA to knockdown eNOS attenuates the H2S-angiogenic effect [47]. 
Furthermore, L-arginine (the substrate of NOS) induces neovessel growth in cultured ring 
isolated from wild type mice but not from CSE-KO mice [47]. Therefore, both H2S and NO are 
required for optimal angiogenic activity, yet angiogenesis still proceeds in the presence of either 
H2S or NO alone albeit to a reduced degree.  
Vascular endothelial growth factor (VEGF) is the most powerful stimulator of 
angiogenesis. The down-regulation of CSE gene led to a decrease in VEGF-induced MAPK 
activation and HUVEC motility [46]. The ex vivo aortic ring angiogenesis assay further showed 
that VEGF-elicited elevation in microvessel formation is dramatically hampered in CSE-KO 
mice [46]. Similarly, the genetic suppression of CSE attenuates VEGF-induced proliferation in 
bEnd3 micro-vascular ECs, whereas it does not impair the mitotic effect of basic fibroblast 
growth factor (bFGF) [113]. The influx of Ca2+ triggered by VEGF into ECs might serve as a 
suitable signal to initiate CSE activation and H2S synthesis [11, 110, 145, 147]. H2S also 
stimulates angiogenesis of ischemic tissues. NaHS activated the hypoxia inducible factor 1-α 
(HIF-1α), the transcription factor driving the expression of numerous growth factors [32], in 
capillary ECs harvested from mouse skeletal muscle [141]. This process was mediated by H2S-
induced NO and VEGF release and subsequent increase in EC proliferation under hypoxia [141]. 
These data have been supported by the increase in VEGF expression reported in both ischemic 
heart and peripheral limbs and related to the pro-angiogenic effect exerted by NaHS treatment in 
mice [140]. However, NaHS represses hypoxia-induced HIF-1α protein translation in ECs 
(EA.hy926) [148]. H2S enhances eukaryotic initiation factor 2-α (eIF2-α) phosphorylation, and 
the consequent fall in HIF-1α accumulation resulted in the down-regulation of VEGF 
expression, thus EC proliferation [148]. This discrepancy might be due to the differences in ECs 
isolated from distinct vascular beds and animal species. 
In addition to therapeutic angiogenesis, H2S might be involved in controlling the neo-
vascularisation of growing tumours. NaHS induces Ca2+ influx in higher levels in tumour ECs 
(TECs) harvested from breast cancer (B-TECs) as compared to their healthy counterparts [145]. 
Importantly, NaHS causes a dose-dependent stimulation of B-TEC proliferation but had little 
effect on the control healthy cells [145]. VEGF-induced Ca2+ entry was prevented by CSE 
blockade by PPG, albeit the physiological meaning of this process was not further investigated 
[145]. In consideration of endothelial phenotypic changes observed in ECs isolated from tumour 
samples, the involvement of H2S in supporting tumour vascularisation should, therefore, be 
assessed by focussing on TECs rather on their normal counterparts [145]. 
 
 
6. 6. The roles of H2S and NO in atherosclerosis 
 
EC dysfunction, hypertension, VSMC proliferation and migration, dyslipidemia, 
oxidative stress, and recruitment of inflammatory cells are the important factors involved in the 
development of atherosclerotic lesions [28, 149]. NO and H2S share several athero-protective 
actions, including blood vessel relaxation and regulation of vascular tone, EC regeneration, 
inhibition of leukocyte adhesion, inhibition of platelet clumping to make the blood thinner, and 
prevention of proliferation and migration of VSMCs [150-153]. The role of NO in 
atherosclerosis development has been studied in apolipoprotein E knockout (apoE-KO) mice, 
where L-NAME treatment significantly decreased NO-mediated vascular response and increased 
atherosclerosis development [154]. NOS gene overexpression reduced adhesion molecules 
expression, reduced the inflammatory process, and inhibited VSMC proliferation and migration 
[155, 156]. Another study proved that decreased NO bioavailability in high cholesterol-induced 
vascular dysfunction of rabbit aortic rings was corrected by eNOS gene transfer, which improved 
vascular relaxation in response to acetylcholine [157]. Kuhlencordt et al. [153] studied whether 
eNOS deficiency affects atherosclerosis development using apoE/eNOS DKO mice and found 
that both male and female apoE/eNOS DKO mice showed significantly increased lesion when 
compared to apoE KO mice [153].  
The anti-atherosclerotic role of H2S was explored in recent years.  CSE expression and 
H2S production were significantly decreased during the development of balloon injury-induced 
neointimal hyperplasia in the rat carotid artery, and that exogenous H2S significantly reduced 
neointimal lesion formation [158]. Treatment of apoE-KO mice with NaHS decreased, and with 
PPG increased, atherosclerotic lesion size [159]. NaHS (100 µmol/L for 12 hrs) inhibited ICAM-
1 expression in TNF-alpha-induced HUVECs via the NF-kB pathway [159]. Moreover, NaHS 
administration concentration-dependently (50-200 µM) reduced CX3CR1 and CX3CL1 
expression in mouse peritoneal macrophages as well as CX3CR1-mediated chemotaxis [160]. In 
fat-fed apoE-KO mice, NaHS (1 mg/kg, i.p., daily) attenuated, and PPG (10 mg/kg, i.p., daily) 
exacerbated, the extent of atherosclerotic plaques [160]. H2S (50 µM) attenuated H2O2 and 
oxidized LDL (oxLDL)-mediated endothelial cytotoxicity in HUVECs [161]. GYY4137 (a slow 
H2S releasing molecule) decreased the atherosclerotic plaque formation and partially restored the 
endothelium-dependent relaxation of apoE-KO mouse aorta [162]. The direct evidence for the 
role of endogenous H2S in atherosclerosis development was reported in 2013, demonstrating that 
CSE-KO mice fed with atherogenic paigen-type diet, but not WT mice, developed early fatty 
streak lesions in the aortic root, increased aortic intimal proliferation and aortic adhesion 
molecule expression, and enhanced oxidative stress [28]. These animals also showed increased 
total plasma cholesterol and LDL-cholesterol levels when compared to WT mice fed with the 
same atherogenic diet. NaHS supplementation to atherogenic diet-fed CSE-KO mice improved 
plasma lipid profile and decreased atherosclerotic lesions [28]. Collectively, these studies 
suggest that NO and H2S play similar roles in the prevention of atherosclerosis. The crosstalk 
between NO and H2S in the development of atherosclerosis, however, has not been explored in 
details. 
 
 
6. 7. The roles of H2S and NO in aging 
 
Aging is related to dramatic structural and functional alterations in both cardiac chambers 
and blood vessels, which can explain the age-related increase in cardiovascular risk [163, 164]. 
During aging, ECs undergo senescence, which leads to a reduced angiogenic activity [165, 166]. 
Cellular senescence, an irreversible arrest of cell cycle [167], can be triggered by the reduced 
bioavailability of both H2S and NO. For instance, senescent human aortic ECs (HAECs) 
exhibited higher ICAM-1 expression and lower eNOS activity [168]. Accordingly, the eNOS 
protein isolated from mesenteric arteries in young mice has the dimer configuration, whereas 
eNOS protein from aged mice was mostly uncoupled to monomers [169]. The same study 
revealed that eNOS uncoupling contributed to increased superoxide levels in aged vessels and 
was due to a reduced BH4 availability [169]. The aging-related EC dysfunction is largely 
ascribed to oxidative stress and inflammation [170, 171]. An excess of ROS, superoxide, and 
hydrogen peroxide compromises the vasodilator activity of NO and facilitate the formation of the 
deleterious radicals [170]. Basal NO production and sensitivity to acetylcholine-mediated 
vasodilation in thoracic aorta rings were reduced, whereas the pro-inflammatory reaction of ECs 
was increased in aged mice compared to young mice [172]. In addition, arginase-II (Arg-II) 
expression/activity was higher in senescent ECs, and Arg-II silencing suppressed eNOS-
uncoupling and several senescence markers, such as senescence-associated-β-galactosidase 
activity, p53-S15, p21, and expression of VCAM1 and ICAM1 [173]. Over-expression of Arg-II 
in non-senescent ECs promoted eNOS-uncoupling and enhanced VCAM1/ICAM1 levels [173]. 
Protein nitrotyrosine formation is accompanied with eNOS uncoupling in mesenteric arteries of 
aged mice [169]. Chronic increase in shear stress in mesenteric arteries of aged rats restored EC 
function through increasing NO production and antioxidant capacity, and thus decreasing 
superoxide levels [174]. In soil nematode Caenorhabditis elegans, which is prominent model 
organism for studying aging [175], exposure to H2S increase life span and thermo-tolerance 
compared to control animals [176]. This finding is in accordance with data showing that NaHS 
treatment protects against HUVEC senescence by modulating SIRT1 activity, as mentioned 
above, and against fibroblast aging via S-sulfhydration of Keap1 and Nrf2 activation in 
association with oxidative stress [127].  A recent study revealed that CSE protein expression was 
increased in aorta of aging rats maintained on an ad libitum (AL) diet. However, CSE expression 
was unchanged in rats maintained on a caloric restriction (CR) diet [177]. Furthermore, CR-fed 
animals at ages of 18, 29, and 38 months had lower CSE expression than in AL-fed animals, 
whereas CSE expression at 8 months was not affected by diets [177], suggesting that CR diet 
may help to stabilize the H2S signaling during aging.  
 
6. 8. The roles of H2S and NO in diabetes 
H2S treatment or CSE over-expression protected ECs from the deleterious consequences 
of hyperglycaemia-induced enhancement of ROS formation and attenuated nuclear DNA injury 
[178]. H2S protected against the development of EC dysfunction in aortic tissues incubated in 
medium with elevated glucose concentration (in vitro "hyperglycemia") and reduced the bio-
energetic derangements in ECs [178]. On the other hand, CSE knockdown deteriorated 
hyperglycemia-induced ROS production and led to more severe loss of endothelium-dependent 
relaxant function [178]. Oxidative stress plays a major role in the development of diabetic 
microvascular complications [179]. Non-obese diabetic (NOD) mice, which gradually develop 
type-1 diabetes, exhibited reduced H2S levels in plasma and aortic tissue [180]. The 
administration of exogenous H2S relieved vascular abnormalities by upregulating connexin 40 
and connexin 43 and normalizing NADPH oxidase and PKCε in STZ-injected rats [181]. These 
results have been corroborated by the finding that the circulating levels of H2S were lower in 
STZ-diabetic rats [178]. The same study shows that, under hyperglycaemic condition bEnd3, 
microvascular ECs accelerated H2S consumption due to the mitochondrial formation of ROS, 
which severely affected cell viability and caused nuclear DNA damage and switched cell 
metabolism from oxidative phosphorylation to glycolysis [178]. As expected, these features were 
associated to the impairment of endothelium-dependent relaxations of rat aortic rings exposed to 
high glucose in vitro. EC functionality was restored either by over-expressing CSE or by 
supplying NaHS (100 - 300 µM) [178].  
The observation that ECs failed to produce sufficient amount of NO in diabetes has been 
documented in animal model of the disease [182]. Similarly, loss of insulin signalling in the 
vascular endothelium led to EC dysfunction due to the decrease in NO synthesis, which impaired 
endothelium-dependent vasodilation and accelerated the progression of atherosclerotic lesions in 
apoE KO mice [183]. Likewise, hyperglycemia inhibited eNOS activity in cultured BAECs and 
in the aorta of diabetic rats [184]. All together, these data illustrate the importance of H2S and 
NO in protecting ECs from the deleterious vascular consequences of diabetes.  
 
 
7. Conclusions and perspectives 
The endothelial monolayer lines the luminal surface of all blood vasculature, thereby 
representing the largest input/output device of the whole organism [4]. ECs perceive both 
chemical and physical stimuli incoming from the extracellular microenvironment, translate them 
into the appropriate signaling cascade and react by proper changes in protein activity and/or gene 
expression profile. H2S, the latest member to join the family of gasotransmitters, has been proven 
to utilize the endothelial signaling toolkit in the most favorable way for vascular functions 
without the prerequisite of specific plasma membrane receptors. H2S provides vascular ECs with 
important pro-survival signal: it stimulates angiogenesis, protects from apoptosis and senescence, 
and exerts both anti-inflammatory and anti-atherosclerotic actions. These pro-surviving effects 
gain much more relevance when considering that low concentrations of H2S do not lead to the 
formation of noxious reactive nitrogen species, opposite to what NO does. It is, therefore, 
perceivable to predict that future therapies of cardiovascular pathologies will benefit from H2S-
based intervention in order to correct endothelial dysfunction involved in the diseases. A 
growing body of evidence indicates that the administration of H2S donors might be 
therapeutically useful in the treatment of chronic heart failure, peripheral artery disease, 
hypertension, and atherosclerosis. In addition, CSE might be a potent molecular target to combat 
tumour growth and vascularization.  
The investigation of H2S signaling in vascular endothelium is, however, in its infancy. 
The therapeutic potential of this recently discovered gasotransmitter demands for the full 
comprehension of its downstream decoders before being fully exploited. A number of 
outstanding questions remain to be solved. The cellular effects of H2S and the related molecular 
underpinnings may vary depending on a plethora of factors, such as the types of vascular beds, 
animal species, and experimental setting. For instance, H2S inhibits HIF-α expression under 
hypoxic conditions in HUVECs, whereas it enhances its tissue levels in the ischemic mouse 
femoral artery. Worth of further studies is also the relationship among the signaling pathways 
engaged by H2S in vascular ECs. Taking the calcium signaling as an example, the evidence for a 
physiological role of Ca2+ signaling in H2S-induced EC proliferation is still missing. 
Nevertheless, an increase in intracellular Ca2+ is sufficient to activate different MAPK members 
and PI-3K, which are involved in H2S-driven angiogenesis, EC replication, migration and 
tubulogenesis [185, 186]. The physiological implications of H2S-induced sub-cellular Ca2+ 
waves extend to the stimulation of endothelial KCa channels, including BKCa, IKCa, and SKCa 
channels, whose gating require a local elevation in Ca2+ levels beneath the plasma membrane 
[187].Therefore, H2S might provide Ca2+ pulse that activates BKCa channels while inducing the 
covalent modification that enhance their open probability. It would be interesting to explore the 
kinetic relationship between H2S-modulated Ca2+ level change and KCa channel activation in 
vascular ECs.  
The mechanistic relationship between H2S and NO remains to be untangled. Both NO 
and H2S may be generated upon a raise in [Ca2+]i, but whether and how eNOS and CSE are 
recruited by the same Ca2+/calmodulin signal are not clear.  The source of Ca2+ leading to eNOS 
engagement in large conduit vessels, such as aorta, is provided by store-operated calcium entry 
(SOCE), a Ca2+-permeable conductance activated on depletion of the intracellular Ca2+ reservoir 
[32]. However, in mesenteric arteries, acetylecholine stimulation results in inositol-1,4,5-
trisphosphate (InsP3)-dependent Ca2+ release rather than SOCE [188]. Future studies are 
necessary to understand whether InsP3-evoked Ca2+ mobilization and SOCE are selectively 
associated to CSE and eNOS, respectively. This mechanism would partially explain the 
differential production of NO and H2S in conduit and resistance arteries. Moreover, NO may 
inhibit CSE activity by inducing S-nitrosylation of the enzyme [50], which would render larger 
arteries less sensitive to H2S. This mechanism, i.e. CSE inhibition by NO, would argue against 
the simultaneous production of both gasotransmitters in the same cells, albeit other studies 
reported NO-induced H2S synthesis [189]. Indeed, it is yet to be unraveled how these two 
gasotransmitters interact when presented at the same time. By the same token, when H2S and NO 
donors are simultaneously administrated, their impacts on the vessel tone may be opposite rather 
than synergistic. This scenario is further complicated by the conflicting effects of H2S on NO 
levels. At physiological pH, H2S may react with NO and form nitrosothiols, thereby limiting 
NO’s vasorelaxing (and perhaps pro-angiogenic) activity. Nevertheless, when pH shifts to acidic 
values, H2S serves as cofactor of NO-releasers to liberate NO [190], which might be a crucial 
signalling event during severe vascular disorders and EC dysfunction. It is imperative to 
understand whether both gasotransmitters serve as parallel signalling pathways in the regulation 
of crucial EC processes, such as proliferation, control of the vascular tone, resistance to 
apoptosis, senescence and oxidative stress; or each individual gasotransmitter governs specific 
EC processes. 
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